COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
Condition: Multivessel Coronary Artery Disease · Ischemia · Vulnerable Plaque · Sponsor: Diagram B.V.
About this study
The COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (49)
| Monash Medical | Clayton, Australia | — |
| Hamilton Health Sciences | Hamilton, Canada | — |
| McGill University Health Centre | Montreal, Canada | — |
| Niagara Health System - St. Catherines Site | Saint Catharines, Canada | — |
| Aarhus University Hospital | Aarhus, Denmark | — |
| North-Estonia Medical Centre | Tallinn, Estonia | — |
| Centre Hospitalier Régional Universitaire de Lille | Lille, France | — |
| Clinique Louis Pasteur | Nancy, France | — |
| Charité - Universitätsmedizin Berlin | Berlin, Germany | — |
| Universitätsklinikum Frankfurt | Frankfurt, Germany | — |
| Apex Heart Institute | Ahmedabad, India | — |
| Apollo Hospitals | Bangalore, India | — |
+ 37 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05333068